Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d552ad67a0c5088d1dd230735e4ae6a1 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70539 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
filingDate |
2000-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2009-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2f8eb98ea25848ce4ae44af71a47655 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_669849bf6271e4aa7b2e9b9c6a7f044f |
publicationDate |
2009-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-100558395-C |
titleOfInvention |
Hybrid peptide modulate immune response |
abstract |
The invention provides the antigen presentation of MHC II class and strengthen the crossbred polypeptide.Crossbred has the N-end, comprises mammal Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO:1) and the modification that keeps the antigen presentation enhanced activity thereof; The C-end comprises the polypeptide in the antigenic peptides binding site that is combined in MHC II quasi-molecule or the epitope of class peptide form; And interleave chemical constitution, the terminal and C-end of the N-of covalent bond crossbred.This paper has also described the method that strengthens in the crossbred molecule that works in the mode that is equal to Ii Key peptide in MHC II class antigen presentation of differentiating.The present invention also provides the method for the restricted epitope of a kind of MHI of enhancing II class to the T presented by cells.The present invention also provides in the body and in vitro method.The present invention also provides the method for the chemical compound of differentiating a kind of MHC II class antigen presentation effect. |
priorityDate |
1999-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |